Slide 1: Investor Presentation May 2019
Working to improve your health INVESTOR PRESENTATION MAY 2019
Slide 2: Important Notice
Important Notice This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New Zealand dollars (NZ$)
Slide 3: FY 2019 Highlights
FY 2019 Highlights 42 countries Maxigesic registered in 20 countries Maxigesic launched in $85.1m operating revenue for FY2019 $6.1m INVESTOR PRESENTATION MAY 2019 operating profit and $16.2m improvement on FY2018 $6.9m available cash as at 31 March 2019 – up from 6.7m end of FY2018 3
Slide 4: Revenue Growth
Revenue Growth 10 year operating CAGR of 13% Operating revenue (NZ$m) INVESTOR PRESENTATION MAY 2019 FY2018 FY2019 Australia New Zealand Rest of World Southeast Asia 4
Slide 5: Financial performance - Revenue by region and channel
Financial performance - Revenue by region and channel NZ$000’s FY2017 % of total FY2018 % of total FY2019 % of total Australia 37,063 53.6% 49,193 60.6% 50,304 59.1% YoY growth 32.7% 2.3%/12.6% New Zealand 29,167 42.1% 27,096 33.4% 26,796 31.5% YoY growth -7.1% -1.1%/5.4% Rest of World 1,968 2.8% 3,
Slide 6: Profit and Loss
Profit and Loss NZ#039;000's year ended 31 March 2019 % of 2018 % of revenue revenue Revenue 85,127 81,176 Cost of Sales (44,397) 52.2% (45,880) 56.5% Gross Profit 40,730 47.8% 35,296 43.5% Other Income 2,237 2.6% 1,130 1.4% Selling and distribution expenses (26,540) 31.2% (28,533) 35.1% General and ad
Slide 7: Balance Sheet
Balance Sheet NZ$’000’s year ended 31 March ASSETS 2019 2018 Current Assets Inventories 25,158 24,412 Trade and other receivables 19,187 16,954 Cash and cash equivalents 6,916 6,770 Derivative assets - 176 Total current assets 51,261 48,312 NON-CURRENT ASSETS Property, plant and equipment 357 330 In
Slide 8: Cashflow
Cashflow NZ#039;000's year ended 31 March 2019 2018 Net cash used in operating activities 1,067 (9,167) Net cash used in investing activities (4,884) (5,855) Net cash generated from financing activities 3,723 5,863 Net increase in cash (94) (9,159) Impact of foreign exchange on cash and cash equivalent
Slide 9: Operating profit progress
Operating profit progress 15 10 5 0 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 (5) INVESTOR PRESENTATION MAY 2019 (10) (15) 0 9
Slide 10: Development Progress
Development Progress Maxigesic Tablets registered across all of EU o First Maxigesic IV registration due 2019 o Maxigesic Oral Liquid filings in 23 countries Maxigesic Hot Drink Sachets regulatory filings to commence 2019 Maxigesic Rapid formulation completed successfully INVESTOR PRESENTATION MAY 2
Slide 11: Maxigesic Global Update
MAXIGESIC GLOBAL UPDATE Eastern Europe and Balkans – launches pending 2019 Singapore/Brunei – launched including OTC [primarily oral dose forms] Iraq -Kurdistan launched Korea - Licensing negotiations underway IV licensed IE – launched UAE – sales growth Licensing discussions HK launched 2019 UK – l
Slide 12: Maxigesic Countries sold and ordered
Maxigesic Countries sold and ordered INVESTOR PRESENTATION MAY 2019 12
Slide 13: Example of licensee sales growth
Example of licensee sales growth 1,600,000 1,400,000 1,200,000 1,000,000 800,000 INVESTOR PRESENTATION MAY 2019 600,000 400,000 200,000 13
Slide 14: Maxigesic going forward
Maxigesic going forward Product Maxigesic Tablets Maxigesic IV Maxigesic oral solution Territories 2019 2018 2019 2018 2019 2018 Licensed 125+ 125 -% 68 62 10% 122 118 4% Registered 42 32 28% - - -% - - -% Sold in 20 10 100% - - -% - - -% INVESTOR PRESENTATION MAY 2019 14
Slide 15: Medium Term Plans
Medium Term Plans Further drive International Sales - Accelerate countries launched in - Start to launch new line extensions [Maxigesic IV] Extend International Licensing - Achieve licensing agreement in USA/Canada and LATAM - Explore previously unplanned Territories: China and Japan Licensing Agree